PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan

MT Newswires Live12:35

PELL Bio-Med Technology's (TPE:6949) multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.

The patent, titled "Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same," was granted under application No. 2024-167934.

The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661254312?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661254312","market":"sg","top_or_hot":-1,"title":"PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan","media":"MT Newswires Live","content":"<html><body><p> PELL Bio-Med Technology's (TPE:6949) multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.</p><p>The patent, titled \"Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same,\" was granted under application No. 2024-167934.</p><p>The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-21 12:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PELL Bio-Med Technology's (TPE:6949) multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.</p><p>The patent, titled \"Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same,\" was granted under application No. 2024-167934.</p><p>The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4022","symbol_name":"陆运","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661254312","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661254312","pubTimestamp":1787286911,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PELL Bio-Med Technology's  multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.The patent, titled \"Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same,\" was granted under application No. 2024-167934.The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4022":"陆运","BK4230":"旅客陆运","CAR":"安飞士"},"translate_title":"PELL Bio-Med 多链 CAR-T 技术在日本获得专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5},"content_text":"PELL Bio-Med Technology's (TPE:6949) multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.The patent, titled \"Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same,\" was granted under application No. 2024-167934.The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661254312","isCrawlerRequest":true}